mouse avatar trial, PDX trial

Large-Scale Screenings Using Patient Avatars Aid Clinical Trial Design

As scientists are learning about the heterogeneity between patients that supposedly have the same tumor, they are growing increasingly interested in understanding whether a given compound can be broadly efficacious or only applicable to a subset of patients with the same disease. Patient-derived xenografts (PDXs) are the model of choice to address these questions as… Read more »

conquer drug resistance

Can We Conquer Drug Resistance in Lung Cancer?

At the beginning of the last century lung cancer was a rare disease. However, as early as the end of the 1900s, it had already become the leading cause of preventable death worldwide. In 2016, the disease is expected to cause approximately 158,000 deaths in the United States alone, more than colorectal, breast, and prostate… Read more »


Avatar Trial Identifies New Treatment Route for Melanoma Patients

Melanoma accounts for approximately five percent of all skin cancer cases, yet it is responsible for nearly 75 percent of skin cancer-related deaths. The BRAF gene is frequently mutated in melanoma, leading to aberrant activation of an important growth pathway. Melanoma patients who receive treatment with targeted therapies that inhibit activated BRAF experience an initial… Read more »


The Bloody Business Of Tandem Duplications in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is the most common form of aggressive hematologic malignancy affecting adults. AML is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is a relatively rare disease, however its incidence increases with age, thus… Read more »